Block listing Interim Review

Sep 14, 2023

Advanced Medical Solutions Group plc
(“AMS” or the “Group”)

HomeRNS NewsHolding in CompanyBlock listing Interim Review
RNS Number : 5046M
Advanced Medical Solutions Grp PLC
14 September 2023
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:

Advanced Medical Solutions Group plc

Name of scheme:

Block Scheme for:

1.   Deferred Share Bonus Scheme

2.   Company Share Option Plan

3.   Unapproved Executive Share Option Scheme

4.   Long Term Incentive Plan

5.   Deferred Annual Bonus Scheme

Period of return:

From:

6 March 2023

To:

5 September 2023

Balance of unallotted securities under scheme(s) from previous return:

1. 152,679

2. 182,253

3. 586,952

4. 274,107

5. 246,341

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

1. Nil

2. Nil

3. Nil

4. Nil

5. Nil

Less:  Number of securities issued/allotted under scheme(s) during period:

1. 85,483

2. 40,710

3. 40,766

4. 47,585

5. Nil

 

 

 

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

1. 67,196

2. 141,543

3. 546,186

4. 226,522

5. 246,341

Number and class of securities originally listed and the date of admission:

4,476,264 ordinary shares of 5p each on 6 September 2018

 

Name of contact:

Eddie Johnson

Telephone number of contact:

01606 545506

For further information, please contact:

Advanced Medical Solutions Group plc

Tel: 44 (0) 1606 545508

Chris Meredith, Chief Executive Officer

Eddie Johnson, Chief Financial Officer

Michael King, Investor Relations

Consilium Strategic Communications

Tel: 44 (0) 20 3709 5700

Matthew Neal / Lucy Featherstone

Investec Bank PLC (NOMAD & Broker)

Tel: 44 (0) 20 7597 5970

Gary Clarence / David Anderson

HSBC Bank PLC (Broker)

Tel: 44 (0) 20 7991 8888

Sam McLennan / Joe Weaving / Stephanie Cornish

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.

AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see admedsol.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.